{"title":"埃勒斯病患者注射玻璃体后眼压立即异常升高","authors":"Anya Lev, Oskana Vladimir, Olga Nikolai","doi":"10.18535/jmscr/v11i11.13","DOIUrl":null,"url":null,"abstract":"Introduction In 1880, British ophthalmologist Henry Eales described Eales' disease for the first time(1). Recurrent vitreous hemorrhaging is a hallmark of Eales' disease(2). The systemic anti- tuberculosis and the steroids usually control the disease and subsequently resolve the vitreous hemorrhage(3), but when the vitreous hemorrhage persists, anti-VEGF is an option(4).","PeriodicalId":16362,"journal":{"name":"Journal of Medical Science And clinical Research","volume":"42 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An abnormal immediate increase in the intraocular pressure post-intravitreal injection in patients with Eales disease\",\"authors\":\"Anya Lev, Oskana Vladimir, Olga Nikolai\",\"doi\":\"10.18535/jmscr/v11i11.13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction In 1880, British ophthalmologist Henry Eales described Eales' disease for the first time(1). Recurrent vitreous hemorrhaging is a hallmark of Eales' disease(2). The systemic anti- tuberculosis and the steroids usually control the disease and subsequently resolve the vitreous hemorrhage(3), but when the vitreous hemorrhage persists, anti-VEGF is an option(4).\",\"PeriodicalId\":16362,\"journal\":{\"name\":\"Journal of Medical Science And clinical Research\",\"volume\":\"42 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Science And clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18535/jmscr/v11i11.13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Science And clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18535/jmscr/v11i11.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
导言 1880 年，英国眼科医生 Henry Eales 首次描述了 Eales 病(1)。反复玻璃体出血是 Eales 病的特征(2)。全身抗结核和类固醇通常能控制病情，随后玻璃体出血也会缓解(3)，但当玻璃体出血持续存在时，抗血管内皮生长因子（anti-VEGF）是一种选择(4)。
An abnormal immediate increase in the intraocular pressure post-intravitreal injection in patients with Eales disease
Introduction In 1880, British ophthalmologist Henry Eales described Eales' disease for the first time(1). Recurrent vitreous hemorrhaging is a hallmark of Eales' disease(2). The systemic anti- tuberculosis and the steroids usually control the disease and subsequently resolve the vitreous hemorrhage(3), but when the vitreous hemorrhage persists, anti-VEGF is an option(4).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
